S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
Novo Nordisk Arms Wegovy to Be a Triple Threat
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
Novo Nordisk Arms Wegovy to Be a Triple Threat
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
Novo Nordisk Arms Wegovy to Be a Triple Threat
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
Novo Nordisk Arms Wegovy to Be a Triple Threat
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?

Ocular Therapeutix (OCUL) Earnings Date, Estimates & Call Transcripts

$7.80
-0.19 (-2.38%)
(As of 04/15/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 13Estimated
Actual EPS
(Mar. 11)
-$0.28
Consensus EPS
(Mar. 11)
-$0.28
Skip Charts & View Estimated and Actual Earnings Data

OCUL Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

OCUL Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Ocular Therapeutix Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20241($0.16)($0.16)($0.16) 
Q2 20241($0.13)($0.13)($0.13) 
Q3 20241($0.12)($0.12)($0.12) 
Q4 20241($0.11)($0.11)($0.11) 
FY 20244($0.52)($0.52) ($0.52)

OCUL Earnings Date and Information

Ocular Therapeutix last released its earnings data on March 11th, 2024. The biopharmaceutical company reported ($0.28) EPS for the quarter, meeting the consensus estimate of ($0.28). The company had revenue of $14.80 million for the quarter, compared to analyst estimates of $15.31 million. Ocular Therapeutix has generated ($1.25) earnings per share over the last year (($1.25) diluted earnings per share). Earnings for Ocular Therapeutix are expected to remain at ($0.68) per share in the coming year. Ocular Therapeutix has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 13th, 2024 based off prior year's report dates.

Ocular Therapeutix Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/13/2024
Estimated)
------- 
3/11/2024Q4 2023($0.28)($0.28)-($0.21)$15.31 million$14.80 million
11/7/2023Q3 2023($0.27)($0.51)($0.24)($0.77)$15.41 million$15.08 million
8/7/2023Q2 2023($0.29)($0.27)+$0.02($0.28)$14.64 million$15.19 million
5/8/2023Q1 2023($0.27)($0.31)($0.04)($0.23)$14.02 million$13.37 million
3/6/2023Q4 2022($0.25)($0.24)+$0.01($0.24)$13.60 million$14.08 million
11/7/2022Q3 2022($0.23)($0.30)($0.07)($0.29)$14.71 million$11.97 million
8/8/2022Q2 2022($0.23)($0.28)($0.05)($0.31)$13.81 million$12.27 million
5/9/2022Q1 2022($0.25)($0.22)+$0.03($0.22)$15.03 million$13.19 million
2/28/2022Q4 2021($0.23)($0.23)-($0.23)$14.18 million$12.31 million    
11/8/2021Q3 2021($0.26)($0.23)+$0.03($0.23)$12.13 million$12.15 million    
8/9/2021Q2 2021($0.20)($0.11)+$0.09($0.25)$11.70 million$11.72 million    
5/5/2021Q1 2021($0.20)($0.24)($0.04)($0.24)$8.12 million$7.34 million  

Ocular Therapeutix Earnings - Frequently Asked Questions

When is Ocular Therapeutix's earnings date?

Ocular Therapeutix has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 13th, 2024 based off last year's report dates. Learn more on OCUL's earnings history.

Did Ocular Therapeutix beat their earnings estimates last quarter?

In the previous quarter, Ocular Therapeutix (NASDAQ:OCUL) reported ($0.28) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.28). Learn more on analysts' earnings estimate vs. OCUL's actual earnings.

How much revenue does Ocular Therapeutix generate each year?

Ocular Therapeutix (NASDAQ:OCUL) has a recorded annual revenue of $58.44 million.

How much profit does Ocular Therapeutix generate each year?

Ocular Therapeutix (NASDAQ:OCUL) has a recorded net income of -$80.74 million. OCUL has generated -$1.25 earnings per share over the last four quarters.

What is Ocular Therapeutix's EPS forecast for next year?

Ocular Therapeutix's earnings are expected to stay at ($0.68) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:OCUL) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners